Industry in brief | Probi, Blis, BioGaia, Beiersdorf

Industry in brief | Probi, Blis, BioGaia, Beiersdorf

6 July 2021 - Deborah Wilkes

Probi and Blis Technologies have entered into a long-term strategic collaboration, BioGaia has increased its stake in MetaboGen, and Beiersdorf has appointed two new board members.

Probi partners with Blis

Probiotics specialists Probi and Blis Technologies have entered into a long-term strategic collaboration.

Probi has invested around NZD9 million (USD6 million) in newly-issued shares in New Zealand’s Blis, corresponding to a 13% ownership.

The two companies have also signed a licensing and distribution agreement whereby Probi will manufacture Blis bacterial strains and offer them to its customers around the world.

In addition, the two companies will also collaborate on research and development.

Probi said Blis Technologies was an “innovative probiotic company with clinically-documented bacterial strains for supporting our natural immune defence, preventing infections of the mouth and throat”. The company added that the strains also “contribute to a healthy set of teeth and gums”.

BioGaia increases stake in MetaboGen

BioGaia has increased its stake in MetaboGen, a Swedish company specialising in microbiome research, from 92% to 100%.

The Swedish probiotics specialist paid SEK11.4 million (USD1.32 million) for the additional 8% shareholding in MetaboGen.

Isabelle Ducellier, BioGaia’s chief executive officer, said: “I am convinced that new scientific discoveries from the MetaboGen team will benefit us and most importantly our partners and consumers, as well as contribute to our long-term growth.”

BioGaia announced an initial investment in MetaboGen of SEK12 million in December 2014.

In April 2018, BioGaia became MetaboGen's majority shareholder when it increased its stake from 36% to 62% in a deal worth SEK11.7 million.

BioGaia increased its stake to 92% in July 2018 in a deal worth SEK27.8 million.

Beiersdorf appoints new board members

Beiersdorf has promoted Patrick Rasquinet to its executive board with responsibility for the Pharmacy & Selective division which houses the Eucerin, Hansaplast and La Prairie brands.

He takes over from Vincent Warnery who was recently appointed chief executive officer of Beiersdorf (click here to read the News story).

Rasquinet joined Beiersdorf in 1993 and has led the La Prairie brand since 2010.

The German skincare specialist has also appointed Oswald Barckhahn to the board with effect from 15 October 2021. He will succeed Thomas Ingelfinger who is retiring in 2022.

Barckhahn, who joins from Jacobs Douwe Egberts in the Netherlands, will be responsible for Beiersdorf’s cosmetics business in Europe and North America.

Click tags below for more information on topics:

Probi BioGaia Beiersdorf

Back to Industry News

Share this page: